ChiCTR2300073630 版本V1.1 版本创建时间2023/09/09 15:32:25 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300073630 

最近更新日期:

Date of Last Refreshed on:

2023-07-17 15:07:33 

注册时间:

Date of Registration:

2023-07-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

海南省成人糖尿病风险预警模型的构建与应用

Public title:

Construction and application of adult diabetes risk prediction model in Hainan province

注册题目简写:

English Acronym:

研究课题的正式科学名称:

海南省成人糖尿病风险预警模型的构建与应用

Scientific title:

Construction and application of adult diabetes risk prediction model in Hainan province

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林乐韦华 

研究负责人:

全会标 

Applicant:

Lin Leweihua 

Study leader:

Quan Huibiao 

申请注册联系人电话:

Applicant telephone:

+86 189 7639 0577

研究负责人电话:

Study leader's
telephone:

+86 138 7607 8153

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hk_llw2008@163.com

研究负责人电子邮件:

Study leader's E-mail:

quanhuibiao@aliyun.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国海南省海口市秀英区秀华路19号海南省人民医院内分泌科

研究负责人通讯地址:

中国海南省海口市秀英区秀华路19号海南省人民医院内分泌科

Applicant address:

Department of Endocrinology, Hainan General Hospital, 19 Xiuhua Road, Xiuying District, Haikou, Hainan, China

Study leader's address:

Department of Endocrinology, Hainan General Hospital, 19 Xiuhua Road, Xiuying District, Haikou, Hainan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

海南省人民医院

Applicant's institution:

Hainan General Hospital

研究负责人所在单位:

海南省人民医院

Affiliation of the Leader:

Hainan General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医伦研[2022]296号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

海南省人民医院医学伦理委员会

Name of the ethic committee:

Hainan General Hospital Medical Ethics Committe

伦理委员会批准日期:

Date of approved by ethic committee:

2022-07-18 00:00:00

伦理委员会联系人:

陈奕潇

Contact Name of the ethic committee:

Chen Yixiao

伦理委员会联系地址:

中国海南省海口市秀英区秀华路19号海南省人民医院行政楼5楼医学伦理办公室

Contact Address of the ethic committee:

Medical Ethics Office, 5th Floor, Administration Building, Hainan General Hospital, 19 Xiuhua Road, Xiuying District, Haikou, Hainan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 898 6862 2476

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

海南省人民医院

Primary sponsor:

Hainan General Hospital

研究实施负责(组长)单位地址:

中国海南省海口市秀英区秀华路19号海南省人民医院

Primary sponsor's address:

Hainan General Hospital, 19 Xiuhua Road, Xiuying District, Haikou, Hainan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

海南省

市(区县):

海口市

Country:

China

Province:

Hainan

City:

Haikou

单位(医院):

海南省人民医院

具体地址:

中国海南省海口市秀英区秀华路19号

Institution
hospital:

Hainan General Hospital

Address:

19 Xiuhua Road, Xiuying District, Haikou, Hainan, China

经费或物资来源:

海南省重点研发计划项目

Source(s) of funding:

Supported by Hainan Province Science and Technology Special Fund

研究疾病:

糖尿病  

Target disease:

diabetes mellitus

研究疾病代码:

Target disease code:

研究类型:

流行病学研究

Study type:

Epidemilogical research

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

(1)根据海南省糖尿病前期及糖尿病流行病学调查,挖掘糖尿病前期及糖尿病风险因素信息。 (2)根据GWAS研究结果,筛选与糖尿病前期及糖尿病相关的SNP位点。 (3)构建并验证海南省成人糖尿病疾病预测模型。  

Objectives of Study:

(1) According to the epidemiological investigation of prediabetes and diabetes in Hainan Province, the information of prediabetes and risk factors of diabetes was excavated. (2) According to the results of GWAS study, the SNP loci related to prediabetes and diabetes were screened. (3) To construct and verify the prediction model of adult diabetes in Hainan province.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)均符合糖尿病前期及2型糖尿病诊断标准;
(2) 年龄 18 周岁以上;
(3) 具备知情同意书。

Inclusion criteria

(1)All participants meet the diagnostic criteria of prediabetes and type 2 diabetes;
(2)All participants are over 18 years old;
(3)All participantsthey have informed consent.

排除标准:

(1)有语言认知障碍者;
(2) 合并严重心、肺、肾、肝等功能衰竭;
(3) 有恶性肿瘤者;
(4)数据不完整或分析困难患者。
(5) 经研究医师判断存在任何影响研究依从性的情况。

Exclusion criteria:

(1) History of language cognitive impairment;
(2) Complicated with severe heart, lung, kidney, liver and other failure Situation;
(3) History of malignant tumor;
(4) Incomplete data or difficulty in analysis
(5) It was judged by the research physician that there was any situation that affected the compliance of the study.

研究实施时间:

Study execute time:

From 2022-09-07 00:00:00 To 2025-09-07 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-17 00:00:00 To 2024-08-31 00:00:00

干预措施:

Interventions:

组别:

糖尿病前期人群

样本量:

3000

Group:

Pre diabetes population

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

2型糖尿病患者

样本量:

3000

Group:

Patients with type 2 diabetes

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

正常对照人群

样本量:

3000

Group:

Normal control population

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

海南省 

市(区县):

 

Country:

China

Province:

Hainan

City:

单位(医院):

海南省人民医院 

单位级别:

三甲 

Institution
hospital:

Hainan General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

身高

指标类型:

附加指标

Outcome:

heght

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

附加指标

Outcome:

body weight

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围

指标类型:

附加指标

Outcome:

waist circumference

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重指数

指标类型:

附加指标

Outcome:

body mass index

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

fasting blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹胰岛素

指标类型:

次要指标

Outcome:

fasting insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

附加指标

Outcome:

TG

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

附加指标

Outcome:

TC

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白胆固醇

指标类型:

附加指标

Outcome:

HDL

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

附加指标

Outcome:

LDL

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后2小时血糖

指标类型:

次要指标

Outcome:

2 hours postprandial blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后2小时胰岛素

指标类型:

次要指标

Outcome:

2 hours postprandial insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全基因组SNPs分型

指标类型:

主要指标

Outcome:

Genone-wide SNPs typing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ROC曲线

指标类型:

主要指标

Outcome:

ROC curve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

灵敏度

指标类型:

主要指标

Outcome:

sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

主要指标

Outcome:

specificity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确度

指标类型:

主要指标

Outcome:

accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血夜

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开,中国临床试验公共管理平台ResMan(www.medresman.org)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the trial complete.China clinical trial public management platform ResMan(www.medresman.org)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form.CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-07-17 15:07:12